2017-03-16,Catabasis Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Recent Corporate Highlights
2017-03-15,Catabasis Pharmaceuticals To Present At Oppenheimer's 27th Annual Healthcare Conference
2017-03-13,Catabasis Pharmaceuticals To Present At The 2017 Muscular Dystrophy Association Scientific Conference
2017-03-02,Catabasis Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Financial Results And Recent Corporate Developments On Thursday, March 16
2017-03-01,Catabasis Pharmaceuticals To Present At Cowen And Company 37th Annual Health Care Conference
2017-02-17,Catabasis Pharmaceuticals Announces Promotion Of Ted Hibben To Chief Business Officer
2017-02-02,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Catabasis Pharmaceuticals, Inc.
2017-01-31,Catabasis Pharmaceuticals Announces Top-Line Results For Part B Of The MoveDMD® Trial For Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy
2017-01-19,Catabasis Pharmaceuticals Phase 1 Data On Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy Being Developed For Duchenne Muscular Dystrophy, Published In The Journal Of Clinical Pharmacology
2017-01-05,Catabasis Pharmaceuticals Research On CAT-5571, A Novel Activator Of Autophagy And Potential Oral Treatment For Cystic Fibrosis, Published In Journal Of Medicinal Chemistry
2017-01-04,Positive Preclinical Research On The Edasalonexent (CAT-1004) Program, A Potential Disease-Modifying Therapy For Duchenne Muscular Dystrophy, Published In JCI Insight
2016-11-17,Catabasis Pharmaceuticals Provides Edasalonexent And Rare Disease Pipeline Updates At Investor Day
2016-11-10,Catabasis Pharmaceuticals Reports Third Quarter 2016 Financial Results And Recent Corporate Highlights
2016-11-03,Catabasis Pharmaceuticals To Host Investor Day In New York City On November 17
2016-10-27,Catabasis Pharmaceuticals Presents Positive Data For CAT-5571, A Novel Activator Of Autophagy, As A Potential Oral Treatment For Cystic Fibrosis At The 30th Annual North American Cystic Fibrosis Conference
2016-10-26,Catabasis Pharmaceuticals To Report Third Quarter 2016 Financial Results And Recent Corporate Developments On Thursday, November 10
2016-10-20,Catabasis Pharmaceuticals To Present CAT-5571, A Novel Activator Of Autophagy, As A Potential Treatment For Cystic Fibrosis At The 30th Annual North American Cystic Fibrosis Conference
2016-10-11,Catabasis Pharmaceuticals To Present The MoveDMD® Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The American Neurological Association's 2016 Annual Meeting
2016-10-06,Catabasis Pharmaceuticals Presents Positive Data From Part A Of The MoveDMD® Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The World Muscle Society Congress
2016-10-05,Catabasis Pharmaceuticals Announces Promotion Of Andrew Nichols, Ph.D. To Chief Scientific Officer And Angelika Fretzen To Senior Vice President Of Product Development
2016-10-04,Catabasis Pharmaceuticals Completes Target Enrollment For Part B Of The MoveDMD® Trial, A Phase 2 Trial Of Edasalonexent (CAT-1004) For The Potential Treatment Of Duchenne Muscular Dystrophy
2016-09-29,Catabasis Pharmaceuticals And Sarepta Therapeutics Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy
2016-09-28,Catabasis Pharmaceuticals Announces Closing Of $11.5 Million Offering Of Common Stock, Including Full Exercise Of Underwriter's Option To Purchase Additional Shares
2016-09-23,Catabasis Pharmaceuticals Announces Pricing Of $10 Million Offering Of Common Stock
2016-08-11,Catabasis Pharmaceuticals Reports Second Quarter 2016 Financial Results And Recent Corporate Highlights
2016-08-09,Catabasis Pharmaceuticals To Present At 2016 Wedbush PacGrow Healthcare Conference
2016-07-28,These 5 Stocks Under $10 Are Set to Soar Higher
2016-07-28,Catabasis Pharmaceuticals To Report Second Quarter 2016 Financial Results And Recent Corporate Developments On Thursday, August 11
2016-07-12,Catabasis Pharmaceuticals Names Joseph Johnston VP, Regulatory Affairs
2016-07-07,Catabasis Pharmaceuticals Announces The Initiation Of An Open-Label Extension For The MoveDMD® Trial Studying Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy
2016-06-26,7 Stocks Under $10 to Trade for Big Post-Brexit Gains
2016-06-20,Catabasis Pharmaceuticals To Present Edasalonexent (CAT-1004), An Oral Agent Targeting NF-kB: MoveDMDSM Trial In Duchenne Muscular Dystrophy (DMD) At The 2016 PPMD Annual Connect Conference
2016-06-08,Catabasis Pharmaceuticals And Parent Project Muscular Dystrophy To Host A Webinar On MoveDMDSM: A Clinical Trial Of Edasalonexent (CAT-1004) In Boys With Duchenne Muscular Dystrophy
2016-06-07,Catabasis Pharmaceuticals Announces Top-Line Phase 2a Results For CAT-2054
2016-05-21,Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data At Digestive Disease Week 2016; Data Support CAT-2054, A Phase 2 Asset, As A Potential Treatment For Nonalcoholic Steatohepatitis (NASH)
2016-05-16,Catabasis Pharmaceuticals To Present Pre-Clinical Data Supporting CAT-2054 As A Potential Treatment For Nonalcoholic Steatohepatitis (NASH) At Digestive Disease Week 2016
2016-05-16,Catabasis Pharmaceuticals To Present CAT-2054, A Potential Treatment For Nonalcoholic Steatohepatitis (NASH) And Hypercholesterolemia, At The National Lipid Association 2016 Scientific Sessions
2016-05-12,Catabasis Pharmaceuticals Reports First Quarter 2016 Financial Results And Recent Corporate Highlights
2016-04-28,Catabasis Pharmaceuticals To Report First Quarter 2016 Financial Results And Recent Corporate Developments On Thursday, May 12
2016-04-12,Catabasis Pharmaceuticals Initiates Part B Of The MoveDMDSM Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
2016-04-07,Catabasis Pharmaceuticals To Present At Needham And Company's 15th Annual Healthcare Conference
2016-04-06,Catabasis Pharmaceuticals Announces Additions To Board Of Directors And The Formation Of A Science And Technology Committee
2016-04-01,Catabasis Pharmaceuticals Announces Resignation Of Chief Financial Officer
2016-03-21,Catabasis Pharmaceuticals Presents Positive CAT-1004 Data From Part A Of The MoveDMDSM Trial At The 2016 Muscular Dystrophy Association Clinical Conference
2016-03-18,Catabasis Pharmaceuticals To Present CAT-1004 Data From Part A Of The MoveDMDSM Trial At The 2016 Muscular Dystrophy Association Clinical Conference
2016-03-04,5 Stocks Poised for Big Breakouts
2016-03-02,Catabasis Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results And Recent Corporate Developments
2016-03-02,Catabasis Pharmaceuticals To Present At Cowen And Company's 36th Annual Health Care Conference
2016-02-17,Catabasis Pharmaceuticals To Report Fourth Quarter And Full Year 2015 Financial Results And Recent Corporate Developments On Wednesday, March 2
2016-02-10,Catabasis Pharmaceuticals Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The XIV International Conference On Duchenne And Becker Muscular Dystrophy
2016-02-05,Muscular Dystrophy Association To Collaborate With Catabasis Pharmaceuticals On Development Of CAT-1004, A Potential Novel Oral Disease-Modifying Treatment For Duchenne Muscular Dystrophy
2016-01-25,Catabasis Pharmaceuticals Announces Positive Top-Line Results From Part A Of The MoveDMD¿ Trial, A Phase 1 / 2 Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
2016-01-19,FARA Announces Catabasis Pharmaceuticals As The Recipient Of The Kyle Bryant Translational Research Award To Evaluate CAT-4001 As A Potential Therapy For Friedreich's Ataxia
2015-12-18,Catabasis Pharmaceuticals Completes Enrollment For Part A Of The MoveDMDSM Trial, A Phase 1/2 Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
2015-12-17,Catabasis Names Deirdre Cunnane SVP, General Counsel
2015-12-09,Catabasis Pharmaceuticals Announces First Patient Dosed In Phase 2a Trial Of CAT-2054 For The Treatment Of Hypercholesterolemia
2015-12-02,Catabasis Pharmaceuticals To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-11-19,Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy
2015-11-12,Catabasis Pharmaceuticals Reports Third Quarter 2015 Financial Results And Recent Corporate Highlights
2015-10-27,Catabasis Pharmaceuticals Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The Action Duchenne International Conference
2015-10-26,Catabasis Pharmaceuticals To Report Third Quarter 2015 Financial Results And Recent Corporate Developments On Thursday, November 12
2015-10-26,European Commission Grants Orphan Medicinal Product Designation For CAT-1004, Catabasis Pharmaceuticals' Investigational Therapy For The Treatment Of Duchenne Muscular Dystrophy
2015-09-25,Catabasis Pharmaceuticals Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The World Muscle Society Congress
2015-09-14,Catabasis Pharmaceuticals Receives Rare Pediatric Disease Designation From FDA For CAT-1004 For The Potential Treatment Of Duchenne Muscular Dystrophy
2015-09-02,Catabasis Pharmaceuticals To Participate In The Citi 10th Annual Biotech Conference And Present At The NewsMakers In The Biotech Industry Conference
2015-08-13,Catabasis Pharmaceuticals Reports Second Quarter 2015 Financial Results And Recent Corporate Highlights
2015-08-13,Catabasis Pharmaceuticals Announces Positive Top-line Phase 1 Data For Hypercholesterolemia Product Candidate CAT-2054
2015-08-11,Catabasis Pharmaceuticals To Present At The American Chemical Society National Conference
2015-08-04,Catabasis Pharmaceuticals To Present At The Wedbush PacGrow Healthcare Conference
2015-07-28,Catabasis Pharmaceuticals Will Present The CAT-2000 Program Of SREBP Modulators For Hyperlipidemias At The Kern Lipid Conference
2015-07-27,Catabasis Pharmaceuticals And UT Southwestern Medical Center Enter Into A Sponsored Research Agreement For CAT-2000 Series In Serious Lipid Disorders
2015-07-06,Catabasis Pharmaceuticals Receives FDA Fast Track Designation For CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
2015-06-30,Catabasis Pharmaceuticals Announces Closing Of Initial Public Offering
2015-06-25,Catabasis Pharmaceuticals Announces Pricing Of Initial Public Offering
,
,
,
